- Beam Therapeutics ended Q3 2026 with $1B in cash, cash equivalents, and marketable securities.
Beam Therapeutics reported $1B in cash, cash equivalents, and marketable securities at the end of the third quarter of 2026. The cash position is a key metric for a clinical-stage biotech, indicating runway for operations and R&D without near-term dilution. Investors will watch for upcoming earnings details on cash burn and pipeline progress.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.